Cardioprotective effects of pitavastatin on cardiac performance and remodeling in failing rat hearts

American Journal of Hypertension

Volumn 22, Issue 2, 2009, Pages 176-182

  Kobayashi, Naohiko ^a   Takeshima, Hiroshi ^a   Fukushima, Hiromichi ^a   Koguchi, Wataru ^a   Mamada, Yasuko ^a   Hirata, Hisato ^a   Machida, Yoshifumi ^a   Shinoda, Motoo ^a   Suzuki, Noriko ^a   Yokotsuka, Fumie ^a   Tabei, Kyoko ^a   Matsuoka, Hiroaki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ACTIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRONECTIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYOSIN LIGHT CHAIN; PHOSPHATIDYLINOSITOL 3 KINASE; PITAVASTATIN; PROTEIN KINASE B; PROTEIN KINASE C BETA; PROTEIN P110; PROTEIN P85; PROTEIN P90; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; S6 KINASE; TRANSCRIPTION FACTOR RELA; WORTMANNIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; DOWN REGULATION; DRUG EFFICACY; ENZYME PHOSPHORYLATION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE COMPLIANCE; HEART PERFORMANCE; HEART PROTECTION; HEART VENTRICLE REMODELING; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AMIDES; ANDROSTADIENES; ANIMALS; CARDIOTONIC AGENTS; HEART; HEART FAILURE; MALE; NADPH OXIDASE; NITRIC OXIDE SYNTHASE TYPE III; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; QUINOLINES; RATS; RATS, INBRED DAHL; RHOA GTP-BINDING PROTEIN; VENTRICULAR REMODELING;

EID: 58549090099     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2008.333     Document Type: Article

References (29)

1. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanism. New Engl J Med 1995; 332: 512-521.
2. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids of clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-1445.
3. Ichihara S, Noda A, Nagata K, Obata K, Xu J, Ichihara G, Oikawa S, Kawanishi S, Yamada Y, Yokota M. Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure. Cardiovasc Res 2006; 69: 726-735.
4. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, Wen J, Takeshita A. Fluvastatin, a 3-hydroxy-3-methylglutaryl Coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infraction. Circulation 2002; 105: 868-873.
5. Brunner F, Maier R, Andrew P, Wolkart G, Zechner R, Mayer B. Attenuation of myocardial ischemia/reperfusion injury in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Cardiovasc Res 2003; 57: 55-62.
6. Inoko M, Kihara Y, Morii I, Fujiwara H, Sasayama S. Transition from compensatory hypertrophy to dilated, failing left ventricles in Dahl salt-sensitive rats. Am J Physiol 1994; 267: H2471-H2482.
7. Kobayashi N, Yoshida K, Nakano S, Ohno T, Honda T, Tsubokou Y, Matsuoka H. Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension 2006; 47: 671-679.
8. Kobayashi N, Higashi T, Hara K, Shirataki H, Matsuoka H. Effects of imidapril on NOS expression and myocardial remodelling in failing heart of Dahl-salt sensitive hypertensive rats. Cardiovasc Res 1999; 44: 518-526.
9. Kobayashi N, Nishikimi T, Horinaka S, Ishimitsu T, Matsuoka H. Effects of TCV-116 on expression of NOS and adrenomedullin in failing heart of Dahl salt-sensitive rats. Atherosclerosis 2001; 156: 255-265.
10. Ohno T, Kobayashi N, Yoshida K, Fukushima H, Matsuoka H. Cardioprotective effect of benidipine on cardiac performance and remodeling in failing rat hearts. Am J Hypertens 2008; 21: 224-230.
11. Kobayashi N, Horinaka S, Mita S, Nakano S, Honda T, Yoshida K, Kobayashi T, Matsuoka H. Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts. Cardiovasc Res 2002; 55: 757-567.
12. Kobayashi N, Mita S, Yoshida K, Honda T, Kobayashi T, Hara K, Nakano S, Tsubokou Y, Matsuoka H. Celiprolol activates eNOS through the PI3K-Akt pathway and inhibits VCAM-1 via NF-κB induced by oxidative stress. Hypertension 2003; 42: 1004-1013.
13. Kobayashi N, Ohno T, Yoshida K, Fukushima H, Mamada Y, Nomura M, Hirata H, Machida Y, Shinoda M, Suzuki N, Matsuoka H. Cardioprotective mechanism of telmisartan via PPAR-γ-eNOS pathway in Dahl salt-sensitive hypertensive rats. Am J Hypertens 2008; 21: 576-581.
14. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nature Med 2000; 6: 1004-1010.
15. Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 1999; 253: 239-254.
16. Dulak J, Józkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets 2005; 5: 579-594.
17. Fritz G, Kaina B. Rho GTPases: promising cellular targets for novel anticancer drugs. Curr Cancer Drug Targets 2006; 6: 1-14.
18. Rikitake Y, Kim HH, Huang Z, Seto M, Yano K, Asano T, Moskowitz MA, Liao JK. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005; 36: 2251-2257.
19. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 2005; 97: 1232-1235.
20. Ming XF, Viswambharan H, Barandier C, Ruffieux J, Kaibuchi K, Rusconi S, Yang Z. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 2002; 22: 8467-8477.
21. Griendling KK, Sorescu D, Ushio-Fukui M. NAD(P)H oxidase. Role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.
22. Cox JA, Jeng AY, Sharkey NA, Blumberg PM, Tauber AI. Activation of the human neutrophil nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase by protein kinase C. J Clin Invest 1985; 76: 1932-1938.
23. Yasunari K, Maeda K, Minami M, Yoshikawa J. HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress. Arterioscler Thromb Vasc Biol 2001; 21: 937-942.
24. Maack C, Kartes T, Kilter H, Schäfers HJ, Nickenig G, Böhm M, Laufs U. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 2003; 108: 1567-1574.
25. Laufs U, Kilter H, Konkol C, Wassmann S, Böhm M, Nickenig G. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res 2002; 53: 911-920.
26. Wassmann S, Laufs U, Bäumer AT, Müller K, Konkol C, Sauer H, Böhm M, Nickenig G. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 2001; 59: 646-654.
27. Habibi J, Whaley-Connell A, Qazi MA, Hayden MR, Cooper SA, Tramontano A, Thyfault J, Stump C, Ferrario C, Muniyappa R, Sowers JR. Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. Endocrinology 2007; 148: 2181-2188.
28. Takahashi H, Takeishi Y, Arimoto T, Shishido T, Konta T, Koyama Y, Niizeki T, Kubota I. Pitavastatin inhibits cardiac hypertrophy in a rat model of progressive renal injury. J Cardiovasc Pharmacol 2005; 46: 487-493.
29. Saka M, Obata K, Ichihara S, Cheng XW, Kimata H, Nishizawa T, Noda A, Izawa H, Nagata K, Murohara T, Yokota M. Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure. J Cardiovasc Pharmacol 2006; 47: 770-779.